Xiaoling Wu

TL;DR: The CARITUDE-1 trial as discussed by the authors evaluated the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies.

TL;DR: Aripiprazole monotherapy-as dosed in this study design-was not significantly more effective than placebo in the treatment of bipolar depression at end point (Week 8), and despite early statistical separation on the Clinical Global Impressions Bipolar Version Severity of Illness-Depression score (key secondary end point), aripIPrazole was not superior to placebo at endpoint.

TL;DR: CARTITUDE-1 (NCT03548207) is a chimeric antigen receptor T (CAR-T) cell therapy containing 2 BCMA-targeting single-domain antibodies that presents a newwindow of opportunity for CAR-T cell therapy in patients with central giant cell granuloma.

TL;DR: Cilta-cel is a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity in patients with relapsed/refractory multiple myeloma in the US.

TL;DR: The mammalian target of rapamycin (mTOR) pathway is essential for tumor development, yet mTOR inhibitors have yielded modest results, so this phase 1 study investigated the mTORC1/mTORC2 inhibitor CC‐223 in patients with advanced cancer.